ReviewFrontiers in microbiology2016
A Compendium for Mycoplasma pneumoniae.
Review in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.
- Chlamydia pneumoniae and chronic asthma: Updated systematic review and meta-analysis of population attributable risk.PloS one · 2021Pooled it
- Trial
- Early Risk Stratification for Subsequent Small Airway Dysfunction in Hospitalized Children withChildren (Basel, Switzerland) · 2026Article
- Temporal dynamics of serum Mycoplasma pneumoniae antibodies in patients with acute respiratory infections: a large retrospective study.Annals of clinical microbiology and antimicrobials · 2026Article
- Diagnostic Accuracy of Serological Tests forAnnals of laboratory medicine · 2026Article
- Research progress on the mechanisms of mucus retention after mycoplasma pneumoniae infection.Frontiers in cellular and infection microbiology · 2026Review
- The impact of the COVID-19 pandemic on the epidemiology, clinical manifestations and molecular characteristics ofFrontiers in immunology · 2026Review
- Population structure reveals clade- and region-specific dissemination of macrolide-resistantFrontiers in cellular and infection microbiology · 2026Article
- Article
- Analysis of Clinical Characteristics and Risk Factors of Pediatric Macrolide-ResistantInfection and drug resistance · 2026Article
- A bibliometric analysis of the literature onSouthern African journal of infectious diseases · 2026Review
- Multi-pathogen respiratory surveillance in western China: Synchronized circulation patterns and predictive modeling.iScience · 2025Article
- Sources of essential lipids for Mycoplasma pneumoniae via P116 to target liver and atherosclerotic lesions.Nature communications · 2025Article
- Characterizing the epidemiology ofEmerging microbes & infections · 2025Article
- Growing Threat of Macrolide-ResistantJournal of Korean medical science · 2025Review
- Article
- Etiological characteristics of Mycoplasma pneumoniae infection and macrolide resistance in children in beijing: a retrospective study from 2018 to 2024.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- [Respiratory infection with mucocutaneous lesions : A rare manifestation of a known pathogen].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025Article
- More than Mucositis: Pediatric RIME Following Co-Infection with SARS-CoV-2 andInfectious disease reports · 2025Article
- Epidemiological changes ofMicrobiology spectrum · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Historically, atypical pneumonia was a term used to describe an unusual presentation of pneumonia. Currently, it is used to describe the multitude of symptoms juxtaposing the classic symptoms found in cases of pneumococcal pneumonia. Specifically, atypical pneumonia is a syndrome resulting from a relatively common group of pathogens including Chlamydophila sp., and Mycoplasma pneumoniae. The incidence of M. pneumoniae pneumonia in adults is less than the burden experienced by children. Transmission rates among families indicate children may act as a reservoir and maintain contagiousness over a long period of time ranging from months to years. In adults, M. pneumoniae typically produces a mild, "walking" pneumonia and is considered to be one of the causes of persistent cough in patients. M. pneumoniae has also been shown to trigger the exacerbation of other lung diseases. It has been repeatedly detected in patients with bronchitis, asthma, chronic obstructive pulmonary disorder, and cystic fibrosis. Recent advances in technology allow for the rapid diagnosis of M. pneumoniae through the use of polymerase chain reaction or rapid antigen tests. With this, more effort has been afforded to identify the causative etiologic agent in all cases of pneumonia. However, previous practices, including the overprescribing of macrolide treatment in China and Japan, have created increased incidence of macrolide-resistant M. pneumoniae. Reports from these countries indicate that >85% of M. pneumoniae pneumonia pediatric cases are macrolide-resistant. Despite its extensively studied past, the smallest bacterial species still inspires some of the largest questions. The developments in microbiology, diagnostic features and techniques, epidemiology, treatment and vaccines, and upper respiratory conditions associated with M. pneumoniae in adult populations are included within this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.